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Purpose: Although many patients with hepatocellular carcinoma experience 
recurrence within 2 years after hepatectomy, some patients with T1 and T2 
hepatocellular carcinoma show recurrence-free survival for more than 5 years after 
surgery. This study was designed to analyze the optimal follow-up period on patients 
with T1 and T2 hepatocellular carcinoma (HCC) showing recurrence-free survival 5 
years after surgery. 
Methods: One hundred seventy patients underwent hepatectomy from January 1995 
to December 1999. Numbers of patients with T1 and T2 HCC were 76 and 73, 
respectively. The recurrence patterns of patients experiencing recurrence more than 
5 years after liver resection were analyzed in aspect of clinicopathological features 
and follow-up period.
Results: Thirteen patients experienced recurrence more than 5 years after surgery. 
Only age was found as a significant factor for recurrence. Eight patients were 
checked regularly with 6-month intervals and the others were checked with 
12-month or more intervals. The size of the recurrent tumors in the 6-month 
interval group had a median of 1.1 cm (range, 1 to 4.2 cm) and the size of the 
recurrent tumors in the 12-month or more interval group had a median of 3 cm 
(range, 1.6 to 4 cm). The tumor size was significantly smaller in the 6-month 
interval group.
Conclusion: Though the patients with early stage HCC showed high overall survival, 
some patients experienced a late recurrence of more than 5 years after surgery. 
Patients less than 60 years old with early stage HCC should be checked regularly 
with 6-month intervals even over 5 years after liver resection.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a very common disease in Korea as well as 
throughout the world. Several guidelines recommend treatment strategies [1-3]. Liver 
resection has been recognized as a curative treatment modality of HCC. Mortality 
after liver resection has dramatically decreased due to improved understanding of 
liver anatomy, surgical and anesthetic technique and patient selection [4-7]. Recent 
mortality rates after liver resection is less than 5% and liver resection is usually 
accepted as a safe treatment modality for HCC [4,8,9]. However, the number of 
patients who can receive liver resection is still limited since it is impossible to operate 
on patients with advanced staged HCC or poor liver function [10]. 
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The Barcelona-Clinic Liver Cancer staging system re-
commends liver resection on only very early stage HCC 
[1]. The Asia Pacific Association for the Study of the Liver 
recommends liver resection on solitary or multifocal 
HCC confined to the liver, anatomically resectable, and 
with satisfactory liver function reserve [3]. Additionally, 
those guidelines recommend surveillance for HCC by 
ultrasonography and α-fetoprotein (AFP) every 6 months 
in patients with high risk of HCC development [1-3]. A 
surveillance program is important in detecting HCC early 
in high risk patients. As a result of surveillance, the rate of 
detection for early stage HCC has been increased to 5-10% 
of patients in the West and 30% in Japan [1]. Recent data 
show that the 5-year overall survival rate of patients with 
early stage HCC is similar between liver resection and liver 
transplantation, which is both around 80% [11-13]. Among 
those patients, some showed no recurrence during the follow-
up term, which was longer than 5 years after liver resection. 
But others experienced their first recurrence more than 5 
years after liver resection. 
However, there is still a debate about the optimal follow-
up interval in patients having recurrence-free survival of 
more than 5 years after liver resection. We investigated 
the correlation between the follow-up interval and 
clinicopathological features and the recurrence patterns in 
patients having recurrence-free survival of more than 5 years 
after liver resection.
METHODS
Patients
One hundred seventy patients with HCC underwent liver 
resection with curative intent between January 1995 and 
December 1999. Among them, the numbers of patients with T1 
and T2 stage HCC were 76 and 73, respectively according to 
the 7th American Joint Committee on Cancer (AJCC) staging 
system. We retrospectively reviewed the medical records of 
those patients with T1 and T2 HCC.
Preoperatively, all patients were evaluated by AFP and at 
least two image modalities. Functional reserve capacity of 
liver was checked by indocyanine retention rate at 15 minutes 
(ICG R15). The extent of liver resection was decided according 
to the liver function and correlation between tumor and 
vascular structure. 
Follow-up policy
Preoperatively, all patients were regularly checked for tumor 
recurrence by AFP and computer tomographic (CT) scan 
every 3 months during the first 2 years. Then, AFP and CT 
scans were regularly performed every 6 months in patients 
without recurrence. If the elevation of AFP level or suspicious 
nodule on CT was shown, further evaluation was conducted 
by magnetic resonance imaging for intrahepatic lesions and 
positron emission tomography CT scan for extrahepatic 
lesions. Repeat resection, ablation therapy, transcatheter 
arterial chemoembolization or salvage liver transplantation 
was performed according to the extensiveness of tumor and 
liver function. In my institute, however, there is no protocol 
about the optimal follow-up interval for patients who are free 
from recurrence for more than 5 years after liver resection as 
of yet.
Outcome parameters
We assessed the time that recurrence developed after 
liver resection and identified the patients whose recurrence 
developed after more than 5 years after liver resection, which 
is defined as late recurrence in this paper. To determine risk 
factors for late recurrence, clinicopathological characteristics 
including age, gender, tumor marker, size, ICG R15, operation 
type, vascular invasion, and satellite nodule were analyzed. 
In addition, we specifically focused on the difference in HCC 
recurrence patterns by follow-up interval. 
Statistical analysis
Statistical analysis was performed using SPSS ver. 15.0 (SPSS 
Inc., Chicago, IL, USA). All continuous variables are presented 
as a median (range) and all categorical variables as a number 
(percentage).
Disease-free survival (DFS) rate was calculated by the 
Kaplan-Meier method. Comparison between patients with 
recurrence and without recurrence was performed by logistic 
regression analysis. When the difference of variables was 
compared between the different follow-up intervals, the 
Mann-Whitney ranked sum test was used for continuous 
variables and the Fisher exact test for categorical variables. 
Statistical significance was defined as P-value < 0.05.
RESULTS
Baseline characteristics
One hundred forty-nine patients with T1 or T2 HCC 
underwent liver resection with curative intent. Baseline 
characteristics of patients are presented in Table 1. Seventy-
six patients were diagnosed as T1 stage and 73 patients as T2 
stage. Sixty-nine patients underwent major liver resection and 
72 patients had vascular invasion. 
Surgical outcomes
Five-year DFS rates of patients with T1 and T2 stage were 
55.8% and 35.4%, respectively (Fig. 1). Ninety-one patients 
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experienced recurrence within 5 years after liver resection. 
Thirty-four patients with T1 stage and 24 patients with T2 
stage showed recurrence-free survival for more than 5 years 
after liver resection. Among them, eight patients with T1 and 
5 patients with T2 stage had recurrence more than 5 years 
after liver resection. 
Prognostic factors for late recurrence 
We compared the clinicopathological characteristics between 
patients with recurrence and without recurrence at more 
than 5 years after liver resection. The results are presented in 
Table 2. Functional reserve capacity of liver and pathological 
characteristics did not show a significant difference between 
the two groups. Only age of more than 60 years was found as 
a significant prognostic factor (hazard ratio, 0.2; P = 0.03). 
Table 1. Baseline characteristics of patients who underwent liver resection 
for hepatocellular carcinoma (n=149)
Variable Value
Sex
  Male 118 (81.2)
  Female 31 (18.8)
Age (yr) 51 (17–69)
Preoperative AFP (IU/mL) 41.2 (0.5–50,000)
Underlying liver disease
  None 28 (18.8)
  Hepatitis B virus 114 (76.5)
  Hepatitis C virus 4 (2.7)
  Hepatitis B and C virus 1 (0.7)
  Alcohol 2 (1.3)
ICG R15 (%) 9.5 (2–68.3)
Operation type
  Minor resection 80 (59.7)
  Major resection 60 (40.3)
Operation time (min) 235 (90–815)
Transfusion amount (mL) 400 (0–14,000)
Tumor size (cm) 4.5 (0.9–16)
Tumor number
  Single 108 (72.5)
  Multiple 41 (27.5)
Satellite nodule
  No 118 (79.2)
  Yes 31 (20.8)
Vascular invasion
  No 85 (57)
  Yes 64 (43)
7th AJCC T stage
  T1 76 (51)
  T2 73 (49)
Values are presented as median (range) or number (%).
AFP, α-fetoprotein; ICG R15, indocyanine green retention rate at 15 minutes; 
AJCC, American Joint Committee on Cancer.
Fig. 1. Disease-free survival (DFS) rate after liver resection for patients with T1 
and T2 stage hepatocellular carcinoma. Patients with T1 and T2 stage showed 
55.8% and 35.4% 5-year disease-free survival rate, respectively (P = 0.033). AJCC, 
American Joint Committee on Cancer.
Table 2. Risk factors predicting recurrence more than 5 years after liver 
resection
Variable Hazard ratio P-value 95% CI
Age≥60 yr 0.2 0.03 0.047–0.856
Female sex 6 0.1 0.712–50.594
AFP≥200 IU/mL 1.839 0.403 0.441–7.664
ICG R15≥15% 0.688 0.678 0.117–4.038
Operation type
  Major resection 0.417 0.175 0.117–1.479
Tumor number
  Multiple 1.189 0.841 0.22–6.441
Tumor size 1.277 0.105 0.95–1.717
Vascular invasion
  Yes 0.883 0.848 0.247–3.153
Satellite nodule
  Yes 0.325 0.182 0.063–1.691
CI, confidence interval; AFP, α-fetoprotein; ICG R15, indocyanine green retention 
rate at 15 minutes.
thesurgery.or.kr272
JKSSSang Hyun Ahn, et al: Optimal follow-up period in patient with HCC
Follow-up interval 5 years after surgery and recurrence pattern
Among thirteen patients with recurrence more than 5 years 
after liver resection, 8 patients were regularly checked with 
6-month intervals and 5 patients were checked with 12-month 
intervals. The median tumor size showed significant di-
fference (P = 0.045) between the 6-month follow-up group (1.1 
cm) and the 12-month follow-up group (3 cm). Preoperative 
clinicopathological characteristics including tumor marker, 
tumor size, number, and vascular invasion did not show 
significant difference between the 2 groups (data is not 
shown), except ICG R15, which was significantly poorer in the 
12-month follow-up group (ICG R15, 6.5% vs. 14%; P = 0.006). 
Outcomes after late recurrence
The median survival time was 39 months in the 6-month 
interval follow-up group and 31 months in the 12-month 
interval follow-up group after detecting the recurrence. 
Curative treatment such as repeat resection and ablation 
therapy could be applied to 37.5% of the patients in the 
6-month interval follow-up group and 40% of the patients in 
12-month interval follow-up group. There were no significant 
differences between the two groups in survival time and 
curative treatment application. There were more candidates for 
salvage liver transplantation in the 6-month interval follow-up 
group (5, 62.5%) than in the 12-month interval follow-group 
(2, 40%). However, it did not show significant difference.
DISCUSSION
There was one randomized controlled study about the 
benefit of surveillance systems in patients with high risk of 
HCC development [14]. They reported that surveillance systems 
decreased the mortality brought on by HCC development. 
Recently, the number of patients who are diagnosed at early 
stage has increased due to surveillance systems [15] and when 
these patients underwent surgical resection, they showed 
good results. Especially, patients with T1 stage HCC showed 
similar overall survival after liver resection to those after liver 
transplantation [16,17]. 
However, those patients still experienced high recurrence 
rates and most recurrences developed within 2 years after liver 
resection [16,17], though some patients had recurrence more 
than 2 years after liver resection. It might be regarded as a de 
novo development of HCC [18,19]. Sometimes, some patients 
experienced recurrence more than 5 years after liver resection. 
In our study, eight patients with T1 stage HCC and 5 patients 
with T2 stage HCC showed late recurrence at more than 5 
years after liver resection. 
The optimal interval of surveillance is broadly investigated 
in high-risk patients. A six-month interval time is usually 
accepted as the optimal period in consideration of risk-
benefit balance and cost [1,3,20-22]. Tumor marker and 
ultrasonography are useful methods to detect HCC in 
surveillance. However, there is no consensus for optimal 
follow-up period after liver resection. 
Many surgeons have adopted a postoperative follow-up 
interval of 3 months in the first 2 years and 6 months after 
2 years. This interval is commonly accepted as the optimal 
follow-up period [23]. However, there is no consensus about 
the follow-up interval after 5 years.
Our study showed that 8 patients with a 6-month follow-
up interval had smaller tumors than patients with a 12-month 
follow-up interval and the difference was significant (P = 
0.045). Repeat resection and salvage transplantation were 
effective treatment modalities for recurrent HCC. When 
patients with recurrence underwent repeat resection, those 
patients showed superiority in survival rates compared with 
those patients who received nonsurgical treatment [24-26]. 
Some reported that when patients with recurrence within 
Milan criteria underwent salvage transplantation, those 
patients showed similar survival compared with the survival of 
patients who underwent primary liver transplantation [27-30]. 
However, those treatments are limited to only highly select 
patients. In our study, patients who had a 6-month follow-up 
interval, showed a median 1.1 cm-sized tumors compared with 
3 cm-sized tumors in patients who had a 12-month follow-
up interval. Regardless of follow-up interval, most recurrent 
tumors are within Milan criteria; however, the tumors were 
smaller and more easily manageable when the follow-up 
interval was short-term (6 months).
Active hepatitis infection was reported as a prognostic 
factor of long-term prognosis and liver function was also 
reported to be associated with long-term prognosis. Only age 
was associated with prognosis at more than 5 years after liver 
resection in our study. Liver function and hepatitis infection 
status did not show a significant difference. Our study has 
some limitations. We checked the causes of underlying liver 
disease, which was mostly due to hepatitis B virus infection. 
However, we did not check the viral replication status or 
the antiviral treatment status. We have been prospectively 
collecting the data to check and analyze the effect of viral 
replication and antiviral treatment on the prognosis.
In conclusion, considering 13 out of 149 patients with T1 
or T2 stage HCC exhibited recurrence more than 5 years 
after liver resection, the risk of late recurrence should not be 
underestimated. When the follow-up interval was short-term, 
6 months, the recurrent tumors were detected at a smaller 
and more easily manageable state. The authors suggested that 
patients less than 60 years old have a 6-month follow-up 
period for easy detection and more effective management of 
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recurrent tumor even 5 years after liver resection.
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